In a head-to-head phase III trial of two drugs that target IL-5 or its receptor, benralizumab was noninferior to mepolizumab for the induction of remission in patients with eosinophilic granulomatosis with polyangiitis.

中文翻译：

---

Benralizumab 对于 EGPA 的治疗效果不劣于美泊利单抗


在两种针对 IL-5 或其受体的药物的头对头 III 期试验中，贝那利珠单抗在诱导嗜酸性肉芽肿性多血管炎患者缓解方面并不劣于美泊利珠单抗。